A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

A 28-Day Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Drug: K-757; Drug: K-757 and open-label sitagliptin; Drug: K-757 and K-833; Drug: Matching placebo to K-757; Drug: Matching placebo to K-757, open-label sitagliptin; Drug: Matching placebo to K-757 and matching placebo to K-833

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Chula Vista, California, United States, 91911
      • ProSciento, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

l. Understand the trial procedures and agree to participate by providing written informed consent.

2. Be willing and able to comply with all trial procedures and restrictions, including following study diet requirements.

3. Be healthy between 18 to 60 years of age, inclusive, at the Screening Visit.

4. Have a Body Mass Index (BMI) ≥27.0 and <35.0 (kg/m2) at the Screening Visit.

5. Be weight stable (<5% variation) over the last 3 months.

6. Be a nonsmoker who has not used tobacco or nicotine-containing products (e.g. nicotine patch, e-cigarettes, vapes) for at least 3 months before administration of the initial dose of trial drug and agrees to abstain from smoking tobacco or the use of nicotine-containing products while on study.

7. Be judged to be in good health by the Investigator, based on clinical evaluations including laboratory safety tests, medical history, physical examination, 12-lead ECG, and vital sign measurements performed at the Screening Visit and before administration of the initial dose of trial drug.

8. Meet the following requirements:

1. Is a male who agrees to all of the following:

   • To use an appropriate method of contraception, including a condom with or without spermicidal cream or jelly, from the first dose of study drug until 14 days after the last dose of study drug. A male subject who had a vasectomy procedure must follow the same restrictions as a non-vasectomized man.
   • If partner is pregnant, to use a condom
   • To not donate sperm from the first dose of study drug until 14 days after the last dose of study drug.

   OR

2. Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:

   • Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a Screening serum follicle-stimulating hormone (FSH) level >30 mIU/mL).
   • Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the subject's recall of their medical history.

Exclusion Criteria:

1. Has participated in another interventional investigational study within 30 days of the Screening Visit. The window will be derived from the date of the last study procedure and/or AE related to the study procedure in the previous study to the Screening Visit of the current study. If the subject received an investigational medication in the prior study, at least 5 half-lives (or longer if required by local regulations) must have passed between the last dose of the investigational product and the Screening Visit.
2. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.
3. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
4. Has a known hypersensitivity or contraindication to any component of K-757 (all Panels), sitagliptin (Panel C only), or K-833 (Panels D and E only), related compounds or their excipients.
5. Has a positive alcohol or drug screen at Screening or admission.
6. Has a positive pregnancy test.
7. Is a lactating/nursing female.
8. Has a positive test result for hepatitis B surface antigen (Ag), hepatitis C virus antibody, or human immunodeficiency (HIV) antibody, at the Screening Visit. Note: Subjects with positive hepatitis B virus or hepatitis C virus serology may be enrolled if quantitative polymerase chain reaction for hepatitis B virus or hepatitis C virus ribonucleic acid is negative.
9. Does not meet study site COVID-19 admission/study participation restrictions.
10. Has a fever (>38°C)*.
11. Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit*.
12. Is unable to refrain from the use of prohibited prescription or non-prescription drugs including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication through completion of study participation. Allowable concomitant medications are limited to 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), ≤2 permissible anti-hypertensive agents, and post-menopausal hormone replacement therapy (HRT). Statin doses must have been stable with reported compliance of at least 80% for ≥3 months prior to the Screening Visit. Anti-hypertensive and HRT doses/regimens must have been stable for ≥1 month prior to the Screening Visit.
13. Has been on any GLP-1 receptor agonist, any dipeptidyl peptidase IV (DPP-4) inhibitor, or any approved or investigational medications known to cause weight loss in the prior 3 months.
14. Has excessive consumption of alcohol within 6 months prior to screening (>14 drinks/week for men and >7 drinks/week for women, where l drink= 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) or use of soft drugs (such as marijuana) within 3 months prior to Screening, or hard drugs (such as cocaine) within 6 months prior to Screening.
15. Is unwilling or unable to refrain from consuming alcohol from 7 days prior to the first dose of study medication through the completion of study participation.
16. Is unable or unwilling to refrain from consumption of Seville oranges, grapefruit, grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids from 2 weeks prior to administration of the first dose of study drug, throughout the study, and until the Follow-up Visit.
17. Is unwilling to refrain from the mustard green family (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, and mustard) or charbroiled meats beginning approximately 48 hours prior to admission to the clinic, if possible (if subject has consumed any of these items prior to admission, the subject may be included in the study and the food and amount should be recorded in the source documents). Subjects will not consume any of the above foods while in the clinical research unit and until the poststudy visit.
18. Has a substance abuse disorder.
19. Had a previous major psychotic disorder.
20. Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening or on Day 1 predose.
21. Has a mean value for triplicate semi-recumbent systolic blood pressure >150 mmHg and/or diastolic blood pressure (BP) >90 mmHg measured after at least 10 minutes at rest at the Screening Visit.
22. Has a screening estimated glomerular filtration rate (eGFR by Modification of Diet in Renal Disease [MDRD]) <60 mL/min/1.73 m2.
23. Has alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >1.0X upper limit of normal (ULN) or total bilirubin >1.2X ULN (isolated bilirubin >1.2X ULN is acceptable if bilirubin is fractionated and direct bilirubin is within the laboratory normal range) at the Screening Visit and Day -1. (Note: Subjects who do not meet this criterion during screening or check-in [Day -1] may not be rescreened/retested).
24. Has serum amylase or lipase >1.2X the ULN at the Screening Visit.
25. Has a recent history (within past 3 years) or current diagnosis of any of the following GI (gastro-intestinal) related diseases: intestinal obstruction, GI perforation, GI motility disorders, adhesions, Clostridium difficile colitis or have had recent unexplained GI bleeding within 3 months prior to screening.
26. Has any history of pancreatitis (acute or chronic), gastroparesis, ischemic colitis, inflammatory bowel disease (IBD), celiac disease, irritable bowel syndrome (IBS), or colitis.
27. Has any past surgical history of gastric banding or bariatric surgery or bowel resection.
28. Has a history of clinically significant endocrine disease including T2DM, a screening HbA1c ≥6.5%, or a history of clinically significant gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, neurologic disorder, neoplastic, or genitourinary abnormalities or diseases.
29. Has a history of unexplained arthralgias (Panel C only).
30. Has a history of bullous pemphigoid (Panel C only).
31. Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

note-* Subject may be included if they are able to return to the site within 7 days of initial screening and the exclusion criterion is no longer met.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

10

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: K-757 (Panel A)	Drug: K-757; administered orally
Experimental: K-757 (Panel B)	Drug: K-757; administered orally
Experimental: K-757 + sitaglipitin (Panel C)	Drug: K-757 and open-label sitagliptin; both administered orally
Experimental: K-757 and K-833 (Panel D)	Drug: K-757 and K-833; both administered orally
Experimental: K-757 and K-833 (Panel E)	Drug: K-757 and K-833; both administered orally
Placebo Comparator: Panel A	Drug: Matching placebo to K-757; administered orally
Placebo Comparator: Panel B	Drug: Matching placebo to K-757; administered orally
Placebo Comparator: Panel C (+ sitagliptin)	Drug: Matching placebo to K-757, open-label sitagliptin; both administered orally
Placebo Comparator: Panel D	Drug: Matching placebo to K-757 and matching placebo to K-833; both administered orally
Placebo Comparator: Panel E	Drug: Matching placebo to K-757 and matching placebo to K-833; both administered orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants who experienced 1 or more treatment-emergent AEs	after treatment with K-757 administered alone, when co-administered with sitagliptin, and when co-administered with K-833	Up to Day 42 +/- 2 days
Proportion of participants who discontinued study medication due to an AE	after treatment with K-757 administered alone, when co-administered with sitagliptin, and when co-administered with K-833	Up to Day 42 +/- 2 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the concentration-time curve [AUC] of plasma K-757	following multiple doses of K-757	Days 1 and 28
Maximum concentration [Cmax] of plasma K-757	following multiple doses of K-757	Days 1 and 28
Time of maximum concentration [Tmax] of plasma K-757	following multiple doses of K-757	Days 1 and 28
Clearance [Cl] of plasma K-757	following multiple doses of K-757	Days 1 and 28
Volume of distribution at steady-state [Vdss] of plasma K-757	following multiple doses of K-757	Days 1 and 28
Half-life [t1/2] of plasma K-757	following multiple doses of K-757	Days 1 and 28
AUC of plasma K-757	following multiple doses of K-757 when co-administered with sitagliptin	Days 1 and 28
Cmax of plasma K-757	following multiple doses of K-757 when co-administered with sitagliptin	Days 1 and 28
Tmax of plasma K-757	following multiple doses of K-757 when co-administered with sitagliptin	Days 1 and 28
Cl of plasma K-757	following multiple doses of K-757 when co-administered with sitagliptin	Days 1 and 28
Vdss of plasma K-757	following multiple doses of K-757 when co-administered with sitagliptin	Days 1 and 28
t1/2 of plasma K-757	following multiple doses of K-757 when co-administered with sitagliptin	Days 1 and 28
AUC of plasma K-757	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
Cmax of plasma K-757	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
Tmax of plasma K-757	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
Cl of plasma K-757	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
Vdss of plasma K-757	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
t1/2 of plasma K-757	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
AUC of plasma K-833	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
Cmax of plasma K-833	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
Tmax of plasma K-833	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
Cl of plasma K-833	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
Vdss of plasma K-833	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28
t1/2 of plasma K-833	following multiple doses of K-757 when co-administered with K-833	Days 14 and 28

Collaborators and Investigators

• Sponsor: Kallyope Inc.

Study record dates

Study Major Dates

• Study Start (Actual): September 21, 2022
• Primary Completion (Actual): May 3, 2023
• Study Completion (Actual): May 31, 2023

Study Registration Dates

• First Submitted: April 7, 2023
• First Submitted That Met QC Criteria: June 9, 2023
• First Posted (Actual): June 12, 2023

Study Record Updates

• Last Update Posted (Estimated): November 22, 2024
• Last Update Submitted That Met QC Criteria: November 20, 2024
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Obesity
• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Body Weight; Overweight; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Hypoglycemic Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Protease Inhibitors; Enzyme Inhibitors; Incretins; Dipeptidyl-Peptidase IV Inhibitors; Sitagliptin Phosphate
• Other Study ID Numbers: K-757 P004

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No